ASLAN Pharmaceuticals Limited (ASLN)
July 26, 2024 - ASLAN Pharmaceuticals Limited was delisted.
0.600
-0.100 (-14.27%)
Inactive · Last trade price on Jul 18, 2024

ASLAN Pharmaceuticals Ratios and Metrics

Millions USD. Fiscal year is Jan - Dec.
Year Ending
Current Dec '23 Dec '22 Dec '21 Dec '20 Dec '19 2018 - 2016
Market Capitalization
2925787065
Upgrade
Market Cap Growth
-77.15%-64.23%-67.82%12.23%6.86%-46.09%
Upgrade
Enterprise Value
10156197562
Upgrade
PE Ratio
--0.20-0.49-2.47-4.10-1.38
Upgrade
PS Ratio
0.140.75---21.69
Upgrade
PB Ratio
-0.59-0.683.001.36-6.65-38.79
Upgrade
P/FCF Ratio
--0.21-0.70-2.29-4.62-2.55
Upgrade
P/OCF Ratio
--0.21-0.70-2.30-4.62-2.55
Upgrade
EV/Sales Ratio
0.831.21---20.50
Upgrade
EV/EBITDA Ratio
--0.37-0.13-0.65-4.83-1.36
Upgrade
EV/EBIT Ratio
-0.61-0.37-0.12-0.64-4.74-1.34
Upgrade
EV/FCF Ratio
--0.34-0.16-0.56-4.95-2.41
Upgrade
Debt / Equity Ratio
-1.48-2.024.510.55-1.87-11.12
Upgrade
Debt / EBITDA Ratio
--0.68-0.80-1.06-1.27-0.41
Upgrade
Debt / FCF Ratio
--0.62-1.05-0.92-1.30-0.73
Upgrade
Quick Ratio
0.941.622.4614.181.364.12
Upgrade
Current Ratio
1.051.842.6314.751.464.14
Upgrade
Asset Turnover
0.330.260000.08
Upgrade
Interest Coverage
-7.90-9.18-12.95-15.98-12.61-50.75
Upgrade
Return on Equity (ROE)
543.80%-8453.60%-190.00%-44.90%188.50%-325.30%
Upgrade
Return on Assets (ROA)
-96.30%-95.70%-67.30%-31.80%-108.90%-123.50%
Upgrade
Return on Capital (ROIC)
-401.40%-323.05%-103.92%-38.21%-181.75%-268.56%
Upgrade
Earnings Yield
-2064.03%-492.35%-204.64%-40.49%-24.41%-72.34%
Upgrade
FCF Yield
-482.45%-143.34%-43.63%-21.65%-39.20%
Upgrade
Buyback Yield / Dilution
-25.91%-17.93%-7.07%-69.43%-18.37%-8.45%
Upgrade
Total Shareholder Return
-25.91%-17.93%-7.07%-69.43%-18.37%-8.45%
Upgrade
Source: Financials are provided by Nasdaq Data Link and sourced from the audited annual (10-K) and quarterly (10-Q) reports submitted to the Securities and Exchange Commission (SEC).